奥精医疗(688613) - 2025 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects to achieve an operating revenue of approximately 223.51 million yuan for the year 2025, an increase of about 17.47 million yuan, representing a year-on-year growth of approximately 8.48%[5] - The net profit attributable to the parent company's shareholders is projected to be around 13.53 million yuan for 2025, an increase of approximately 26.19 million yuan, indicating a turnaround from loss to profit[5] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be around -0.92 million yuan, an improvement of approximately 27.46 million yuan compared to the previous year[5] - In 2024, the company reported an operating revenue of 206.03 million yuan and a net loss attributable to the parent company's shareholders of 12.66 million yuan[7] Factors Influencing Performance - The company attributes the performance improvement to the increased clinical usage of orthopedic artificial bone and the expansion of market share through enhanced production and marketing strategies[9] - The adjustment in the profit forecast is due to higher-than-expected asset impairment losses, leading to a decrease in the net profit after deducting non-recurring items from the previous estimate[10] Forecast Accuracy and Accountability - The company emphasizes that the forecast data is preliminary and has not been audited by an accounting firm, with no significant uncertainties affecting the accuracy of the forecast identified[12] - The board of directors has expressed sincere apologies for the discrepancies in the earnings forecast and commits to improving accounting practices to prevent similar issues in the future[14]